<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04692259</url>
  </required_header>
  <id_info>
    <org_study_id>2020-05708</org_study_id>
    <nct_id>NCT04692259</nct_id>
  </id_info>
  <brief_title>May the Risk of PHLF be Predicted With Preoperative Liver Gadoxetate MRI</brief_title>
  <acronym>MR-Predict</acronym>
  <official_title>Is It Possible To Predict PHLF? - Retrospective Analysis of Gadoxetate MRI Prior To Major Liver Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Linkoeping</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Linkoeping</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post hepatectomy liver failure (PHLF) is one of the most severe complications after liver&#xD;
      re-section. Preoperative evaluation of liver function is complicated and imprecise. The&#xD;
      volume and function needed for each individual patient is unknown and the methods used for&#xD;
      evaluation are uncertain. Preoperative MRI with Gadolinium may give dynamic information&#xD;
      regarding liver function correlating with postoperative liver failure. A retrospective&#xD;
      analysis will be performed regarding this topic.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post hepatectomy liver failure (PHLF) is one of the most severe complications after liver&#xD;
      re-section. Preoperative evaluation of liver function is complicated and imprecise. The&#xD;
      volume and function needed for each individual patient is unknown and the methods used for&#xD;
      evaluation are uncertain. Arbitrary volume limits have been postulated but still there are&#xD;
      patients dying of PHLF with volumes well above these limits.&#xD;
&#xD;
      On multivariate analyses, age â‰¥70 years, pre-operative chemotherapy, steatosis, resection of&#xD;
      &gt;3 segments, vascular reconstruction and intraoperative blood loss &gt;300 mL significantly&#xD;
      increased the risk of PHLF. Combining ISGLS grades B and C groups resulted in a high&#xD;
      sensitivity for predicting mortality compared to the 50-50 rule and Peak bilirubin &gt;7 mg/dL.&#xD;
&#xD;
      For patients with low volume of the future liver remnant (FLR) there are techniques to&#xD;
      in-crease the volume prior to resection. Portal vein embolization (PVE) is an established&#xD;
      meth-od, whereas associating liver partition and portal vein ligation for staged hepatectomy&#xD;
      (ALPPS) is relatively new. Augmentation of the volume of the FLR is indicated for patients&#xD;
      with FLR less than 20%, provided no intrinsic liver disease exists, 30% after chemotherapy&#xD;
      and 40% for patients with compromised liver function, for example liver cirrhosis.&#xD;
&#xD;
      Both methods, PVE and ALPPS, have high risks of morbidity and mortality, especially post&#xD;
      hepatectomy liver failure (PHLF), why other alternatives are evaluated. Liver venous&#xD;
      depri-vation (LVD), adds liver vein/s occlusion with a plug/plugs when PVE is performed or&#xD;
      after PVE. Preliminary data indicate that the growth rate with this percutaneous method is&#xD;
      equivalent to ALPPS with function following in parallel. Still all three methods add one&#xD;
      extra treatment stage to increase liver volume of the FLR but still suffers the risk of PHLF.&#xD;
      Furthermore, a large group of patients is treated with one stage hepatectomy where the volume&#xD;
      and function also may be limited.&#xD;
&#xD;
      Liver volume estimation has been the main method to ensure safe resections, but as many&#xD;
      studies have explored functional tests with the goal of increasing safety. The most used ones&#xD;
      are Indocyanine green (ICG), maximum liver function capacity (LiMax) , Child Pugh (CP) score&#xD;
      and Hepatobiliary scintigraphy (HBS). Still, none of these, alone or in combination have been&#xD;
      able to completely ameliorate this dreadful complication. In addition, the cut-off levels for&#xD;
      resection for each of these methods are arbitrary, mainly because PHLF is relative-ly rare as&#xD;
      are major liver resections. Furthermore, all the tests are time consuming, costly and&#xD;
      demanding for the patients.&#xD;
&#xD;
      The development of liver gadoxetate (=Primovist) MRI has given hope that this method may&#xD;
      provide similar information as that of hepatobiliary scintigraphy (HBS), but with a higher&#xD;
      resolution of liver function on a segmental level and at the same time enable liver volume&#xD;
      estimation of the FLR as well as tumour burden and anatomy. In addition, MRI may also add&#xD;
      quantitative information regarding steatosis, fibrosis (MRE) and iron content, factors&#xD;
      previ-ously not included in any test used to estimate liver function.&#xD;
&#xD;
      So, with one modality most of the information gathered with all the other methods could&#xD;
      possibly be incorporated into one.&#xD;
&#xD;
      Data regarding the increase in volume, as well as function, during the first week after&#xD;
      PVE/ALPPS/LVD is sparse. Previous studies have shown that after PVE the increase in func-tion&#xD;
      in the non-embolized lobe is larger than the increase in volume. The opposite has been shown&#xD;
      for patients operated with ALPPS where the increase in volume was larger than the increase in&#xD;
      function.&#xD;
&#xD;
      HBS has become common in several centers to estimate the liver function prior to major&#xD;
      hepatectomy, including TSH and ALPPS. One disadvantage is the relatively poor spa-tial&#xD;
      resolution which therefore necessitates another radiological study to assess the tumor burden&#xD;
      in the liver. Dynamic gadoxetate MRI has been shown to be comparable with HBS to assess the&#xD;
      liver function, with a very strong correlation between the two methods. Also, in PVE&#xD;
      patients, it strongly indicates the risk of PHLF after resection when there is no in-creased&#xD;
      enhancement in the FLR after 2 weeks.&#xD;
&#xD;
      Liver MRI is increasingly used prior to liver resection for analysis of liver tumour burden&#xD;
      and anatomy. The long-term goal of this project is to find simple functional measures that&#xD;
      can be obtained from the standard clinical MRI used today in everyday clinical practice. In&#xD;
      this way we would ultimately have a method to both evaluate segmental function (gadoxetate),&#xD;
      fat and iron storage, fibrosis, volume, tumour burden and anatomy.&#xD;
&#xD;
      Study aim The overall aim of this retrospective study is to evaluate if a preoperative MRI&#xD;
      with liver specific contrast agent (gadoxetate, aka Primovist) add segmental functional&#xD;
      information and if this information can be used to predict PHLF more accurate than with FLR&#xD;
      calculation alone. Thus, the result of the functional analysis will be used to identify&#xD;
      factors in the MRI examination that correlates to the risk of PHLF. Based on the gadoxetate&#xD;
      MRI data, a pro-spective clinical trial will be designed afterwards to validate the results&#xD;
      of this retrospective study. The final goal is to establish a pre-operative workup based on a&#xD;
      Primovist MRI proto-col, providing a robust and predictive functional and volumetric measure&#xD;
      in all preoperative examinations. This might contribute to a more accurate risk assessment of&#xD;
      patients sched-uled for hepatcetomy, thus reducing both post-operative, PHLF related&#xD;
      morbidity and mortality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Retrospective analysis of correlation between MRI dynamics and the risk of postoperative liver failure after liver resection.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast dynamics of Gadoxetate MRI correlation with the risk of PHLF.</measure>
    <time_frame>2 years</time_frame>
    <description>MRI dynamics correlation with postoperative liver failure. Measurement of gadoxetate uptake pattern in the liver and correlation of this pattern to the risk of developing post hepatectomy liver failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between preoprative and postoperative risk factors and PHLF</measure>
    <time_frame>2 years</time_frame>
    <description>Multivariable analysis of risk factors for Postoperative liver failure including but not limited to: Charlson score, 50:50 rule, CP, MELD, ICG, renal function, thrombocyte count, signs of portal hypertension (portal vein diameter, spleen size), type of resection, bleeding, operation time, diagnosis, neoadjuvant chemo and preoperative liver volume augmentation, MRI contrast dynamics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI protocol description report on method used MRI protocol description</measure>
    <time_frame>[Time Frame: 2 years</time_frame>
    <description>Presentation of protochol and dynamic analysis used to predict postoperative liver failure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>MRI</condition>
  <condition>Liver Resection</condition>
  <condition>Liver Failure as A Complication of Care</condition>
  <arm_group>
    <arm_group_label>experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm study. All patient who had an MRI performed before liver resection is included</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Liver MRI before liver resection</description>
    <arm_group_label>experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who have had a Primovist MRI within 8 weeks before hemihepatectomy or&#xD;
             extended hemi-hepatectomy +/- bile duct anastomosis independent of diagnosis.&#xD;
&#xD;
          2. Patients with cirrhosis who have had a Primovist MRI within 8 weeks before resection&#xD;
             of more than one liver segment&#xD;
&#xD;
          3. Patients who had liver volume augmentation with a pre-operative Primovist MRI less&#xD;
             than 2 weeks before resection&#xD;
&#xD;
          4. Patients who have had a Primovist MRI within 6 weeks be-fore any liver resection where&#xD;
             PHLF or death within 90 days occurred.&#xD;
&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. &lt;18 years of age&#xD;
&#xD;
          2. Resection was not performed -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per SandstrÃ¶m, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic study</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Per SandstrÃ¶m, Prof</last_name>
    <phone>+46734058581</phone>
    <email>per.sandstrom@liu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bergthor Bjornsson, MD PhD</last_name>
    <phone>+46101033666</phone>
    <email>bergthor.bjornsson@liu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rikshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Noergaard Larsen, MD PhD</last_name>
      <email>penola@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Eva Fallentin, MD</last_name>
      <email>eva.fallentin@regionh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Helsingfors Universitetssjukhus</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ville Sallinen, MD PhD</last_name>
      <email>ville.sallinen@helsinki.fi</email>
    </contact>
    <contact_backup>
      <last_name>Ali Ovissi, MD</last_name>
      <email>ali.ovissi@hus.fi</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BÃ¥rd RÃ¶sok, MD PhD</last_name>
      <email>brosok@ous-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Per SandstrÃ¶m</name>
      <address>
        <city>LinkÃ¶ping</city>
        <state>Ostergotland</state>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per SandstrÃ¶m, Prof</last_name>
      <phone>+46734058581</phone>
      <email>per.sandstrom@liu.se</email>
    </contact>
    <contact_backup>
      <last_name>Bergthor Bjornsson, MD PhD</last_name>
      <phone>+46101033666</phone>
      <email>bergthor.bjornsson@liu.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Huddinge</name>
      <address>
        <city>Stockholm</city>
        <state>SÃ¶dermanland</state>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernesto Sparrelid, MD PhD</last_name>
      <phone>+47708880787</phone>
      <email>ernesto.sparrelid@karolinska.se</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Gilg, MD PhD</last_name>
      <email>stefan.gilg@karolinska.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska sjukhuset</name>
      <address>
        <city>GÃ¶teborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magnus Rizell, MD PhD</last_name>
      <email>magnus.rizell@surgery.gu.se</email>
    </contact>
    <contact_backup>
      <last_name>Leila Faez, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Akademiska sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jozef Urdzik, MD PhD</last_name>
      <email>jozef.urdzik@akademiska.se</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Bjerner, MD</last_name>
      <email>thomas.bjerner@akademiska.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Sultana A, Brooke-Smith M, Ullah S, Figueras J, Rees M, Vauthey JN, Conrad C, Hugh TJ, Garden OJ, Fan ST, Crawford M, Makuuchi M, Yokoyama Y, BÃ¼chler M, Padbury R. Prospective evaluation of the International Study Group for Liver Surgery definition of post hepatectomy liver failure after liver resection: an international multicentre study. HPB (Oxford). 2018 May;20(5):462-469. doi: 10.1016/j.hpb.2017.11.007. Epub 2017 Dec 26.</citation>
    <PMID>29287736</PMID>
  </results_reference>
  <results_reference>
    <citation>Shindoh J, Tzeng CW, Aloia TA, Curley SA, Zimmitti G, Wei SH, Huang SY, Mahvash A, Gupta S, Wallace MJ, Vauthey JN. Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol. 2013 Aug;20(8):2493-500. doi: 10.1245/s10434-012-2864-7. Epub 2013 Feb 3.</citation>
    <PMID>23377564</PMID>
  </results_reference>
  <results_reference>
    <citation>Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006 Oct;13(10):1271-80. Epub 2006 Sep 6.</citation>
    <PMID>16955381</PMID>
  </results_reference>
  <results_reference>
    <citation>Guiu B, Chevallier P, Denys A, Delhom E, Pierredon-Foulongne MA, Rouanet P, Fabre JM, Quenet F, Herrero A, Panaro F, Baudin G, Ramos J. Simultaneous trans-hepatic portal and hepatic vein embolization before major hepatectomy: the liver venous deprivation technique. Eur Radiol. 2016 Dec;26(12):4259-4267. Epub 2016 Apr 18.</citation>
    <PMID>27090112</PMID>
  </results_reference>
  <results_reference>
    <citation>Guiu B, Quenet F, Escal L, Bibeau F, Piron L, Rouanet P, Fabre JM, Jacquet E, Denys A, Kotzki PO, Verzilli D, Deshayes E. Extended liver venous deprivation before major hepatectomy induces marked and very rapid increase in future liver remnant function. Eur Radiol. 2017 Aug;27(8):3343-3352. doi: 10.1007/s00330-017-4744-9. Epub 2017 Jan 18.</citation>
    <PMID>28101681</PMID>
  </results_reference>
  <results_reference>
    <citation>de Graaf W, van Lienden KP, van den Esschert JW, Bennink RJ, van Gulik TM. Increase in future remnant liver function after preoperative portal vein embolization. Br J Surg. 2011 Jun;98(6):825-34. doi: 10.1002/bjs.7456. Epub 2011 Apr 11.</citation>
    <PMID>21484773</PMID>
  </results_reference>
  <results_reference>
    <citation>Sparrelid E, Jonas E, Tzortzakakis A, DahlÃ©n U, Murquist G, Brismar T, Axelsson R, Isaksson B. Dynamic Evaluation of Liver Volume and Function in Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy. J Gastrointest Surg. 2017 Jun;21(6):967-974. doi: 10.1007/s11605-017-3389-y. Epub 2017 Mar 10.</citation>
    <PMID>28283924</PMID>
  </results_reference>
  <results_reference>
    <citation>Cieslak KP, Bennink RJ, de Graaf W, van Lienden KP, Besselink MG, Busch OR, Gouma DJ, van Gulik TM. Measurement of liver function using hepatobiliary scintigraphy improves risk assessment in patients undergoing major liver resection. HPB (Oxford). 2016 Sep;18(9):773-80. doi: 10.1016/j.hpb.2016.06.006. Epub 2016 Jul 25.</citation>
    <PMID>27593595</PMID>
  </results_reference>
  <results_reference>
    <citation>Olthof PB, Tomassini F, Huespe PE, Truant S, Pruvot FR, Troisi RI, Castro C, Schadde E, Axelsson R, Sparrelid E, Bennink RJ, Adam R, van Gulik TM, de Santibanes E. Hepatobiliary scintigraphy to evaluate liver function in associating liver partition and portal vein ligation for staged hepatectomy: Liver volume overestimates liver function. Surgery. 2017 Oct;162(4):775-783. doi: 10.1016/j.surg.2017.05.022. Epub 2017 Jul 18.</citation>
    <PMID>28732555</PMID>
  </results_reference>
  <results_reference>
    <citation>Rassam F, Zhang T, Cieslak KP, Lavini C, Stoker J, Bennink RJ, van Gulik TM, van Vliet LJ, Runge JH, Vos FM. Comparison between dynamic gadoxetate-enhanced MRI and (99m)Tc-mebrofenin hepatobiliary scintigraphy with SPECT for quantitative assessment of liver function. Eur Radiol. 2019 Sep;29(9):5063-5072. doi: 10.1007/s00330-019-06029-7. Epub 2019 Feb 22.</citation>
    <PMID>30796575</PMID>
  </results_reference>
  <results_reference>
    <citation>Theilig D, Steffen I, Malinowski M, Stockmann M, Seehofer D, Pratschke J, Hamm B, Denecke T, Geisel D. Predicting liver failure after extended right hepatectomy following right portal vein embolization with gadoxetic acid-enhanced MRI. Eur Radiol. 2019 Nov;29(11):5861-5872. doi: 10.1007/s00330-019-06101-2. Epub 2019 Mar 21.</citation>
    <PMID>30899977</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 29, 2020</study_first_submitted>
  <study_first_submitted_qc>December 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Linkoeping</investigator_affiliation>
    <investigator_full_name>Per SandstrÃ¶m</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>Postoperative liver failure</keyword>
  <keyword>Gadolinium</keyword>
  <keyword>Liver resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

